United States securities and exchange commission logo

                               March 5, 2021

       Zheng Wei, Ph.D.
       Chief Executive Officer
       Connect Biopharma Holdings Limited
       Science and Technology Park
       East R&D Building, 3rd Floor
       6 Beijing West Road, Taicang
       Jiangsu Province, China 215400

                                                        Re: Connect Biopharma
Holdings Limited
Statement on Form F-1
                                                            Filed February 26,
                                                            File No. 333-253631

       Dear Dr. Wei:

                                                        We have reviewed your
registration statement and have the following comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Registration Statement on Form F-1

       Description of American Depositary Shares
       Jurisdiction and Arbitration, page 210

   1.                                                   We note your disclosure
that the arbitration provisions of the deposit agreement "do not
                                                        preclude [ADS holders]
from pursuing claims under the Securities Act or the Exchange
                                                        Act in federal or state
courts." Please ensure, if true, that the deposit agreement clearly
                                                        states that the
arbitration provisions do not apply to claims under the Securities Act or the
                                                        Exchange Act.
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.
 Zheng Wei, Ph.D.
Connect Biopharma Holdings Limited
March 5, 2021
Page 2

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration

       You may contact Eric Atallah at 202-551-3663 or Vanessa Robertson at
202-551-3649 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Ada D. Sarmento at 202-551-3798 or Tim Buchmiller at 202-551-3635 with
any other

FirstName LastNameZheng Wei, Ph.D.
                                                           Division of
Corporation Finance
Comapany NameConnect Biopharma Holdings Limited
                                                           Office of Life
March 5, 2021 Page 2
cc:       Patrick A. Pohlen, Esq.
FirstName LastName